Asterand plc is the leading global provider of high quality, well characterized human tissue and human tissue-based research solutions to drug discovery scientists. (Our mission is to provide human-based solutions to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success).
Asterand plc has a well established human tissue heritage, having been formed in 2006 through the merger of Asterand (founded 2000), a human tissue biorepository and Pharmagene (founded 1996) a human tissue-based drug discovery company. Our expertise has been further strengthened following the acquisition of BioSeek in February 2010. BioSeek (founded 2000) brings proprietary, primary cell-based models of human disease biology that provide early insight into human pharmacological and toxicological properties of compounds through comparison of resulting data profiles with an established and growing database of profiles for known compounds.
With this background and capability in human tissue procurement, characterization and research, Asterand is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical, biotechnology and diagnositic companies, as well as academia. From our offices in Detroit, MI Royston, U.K. and San Francisco, CA, we have more than 100 employees focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety.
Keeping Tumor Growth at Bay Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.Future of Medicine Could be Found in a Tiny Crystal Ball A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.Improving Delivery of Poorly Soluble Drugs Using Nanoparticles A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.Faster Drug Discovery? Startup develops more cost-effective test for assessing how cells respond to chemicals.New Mechanism of Antitumor Action Identified A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.Nanoparticles Deliver Tumor Suppressors to Damaged Livers UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.Experimental Combination Surprises with Anti-HIV Effectiveness A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.A New Type of Anticancer Agent Success in the development of a ?-tubulin specific inhibitor.Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs” In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.Versatile New Molecule-Building Technique Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.